



Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX RELEASE

Presentation: Telix's AI Development Program and Dedicaid Acquisition

Melbourne (Australia) – 27 April 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) refers to the announcement lodged with the ASX today (27 April 2023) regarding the agreement to acquire Vienna-based Dedicaid GmbH (Dedicaid), a spin-off of the Medical University Vienna.

The attached presentation provides further information regarding Telix's Artificial Intelligence (AI) strategy and development platform.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [Twitter](https://twitter.com/TelixPharma) (@TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals-limited).

Telix's lead product, gallium-68 (⁶⁸Ga) gozetotide (also known as ⁶⁸Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),¹ and by the Australian Therapeutic Goods Administration (TGA),² and by Health Canada.³ Telix is also progressing a marketing authorisation application for this investigational candidate in the United Kingdom.⁴

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking

¹ Telix ASX disclosure 20 December 2021.

² Telix ASX disclosure 2 November 2021.

³ Telix ASX disclosure 14 October 2022.

⁴ Telix ASX disclosure 3 April 2023.

statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website.

©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).




Dedicaid Acquisition

**Adding a new dimension of
clinical decision support to our
Artificial Intelligence (AI) platform**

Telix Pharmaceuticals (ASX:TLX)

27 April 2023



Disclaimer

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this presentation together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this presentation, whether as a result of new information, future developments or a change in expectations or assumptions.

Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been approved by the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada.

Full United States prescribing information for Illuccix can be found at <http://illuccixhcp.com/s/illuccix-prescribing-information.pdf>

The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.



Contents

04 AI in healthcare and medical imaging

05 Telix's AI strategy

06 Telix's AI platform

10 Dedicaid acquisition rationale

11 Telix AI™: next steps

The role of AI in healthcare and medical imaging

Despite major advances, challenges remain in routine clinical diagnosis

The increased use of medical imaging is creating multiple workforce challenges:

- **Manual image processing** and clinical “reading” is a **highly specialised and time-consuming** task
- Clinicians do not have time to **extract all relevant information** from images and therefore the **full value of data is not being utilised**
- There is potential for **differential interpretation** between clinicians for image-based diagnosis
- **Longitudinal analysis** of images (over time) is critical to monitoring disease progression and treatment response

AI can help to overcome these challenges and optimise image-based diagnosis:

- Helps clinicians **better understand data** presented and **assists with harmonisation and interpretation**, especially identifying even small trends/changes over time
- Enables clinicians and institutions with routine tasks to become **more efficient**, and manage **more patients** in a timely manner
- Enables the clinician to make **more accurate** and **quantitative disease diagnosis**
- Provides **personalised disease predictions** such as risk, optimised treatment options and response

Telix's AI strategy

Earlier, more accurate diagnosis, and personalised disease predictions



Diagnosis, prediction and productivity

A platform that addresses key clinical and workforce needs:

- **Image reading:** Automated lesion segmentation and classification
- **Clinical decision support:** Personalised medicine
- **Clinical trial efficiency:** e.g. patient selection and productivity improvement



Aligned to our theranostic pipeline

- Applicable to multiple disease indications, e.g. prostate, kidney, glioma
- **Further enhances the value of imaging – can interpret complex data** from multiple sources to **inform clinical decisions**
- Extracting **greater utility** out of data from previous and ongoing clinical trials



Commercial edge

- Favourably **differentiated from competitor solutions**
- Ability to **rapidly build** applications
- **Near-term** regulatory submissions are feasible based on the maturity level of the current platform

Supercharging our AI platform: Telix AI™

The Dedicaid acquisition adds a new dimension of clinical support



Reader Support (existing)¹

Increases efficiency and reproducibility of imaging assessments:

- Automates lesion segmentation
- Automates identification of PSMA lesions including low SUV (<3) uptake
- Future potential to track individual lesions between scans to show changes over time



Clinical Decision Support²

D E D I C A I D

Predicts disease outcomes including potential risk, severity and response to treatment:

- Automated machine learning (AutoML) platform can generate indication-specific applications for use with PET³ and other imaging modalities
- Predictive capabilities differentiated from commercially available AI solutions
- In prostate cancer can reliably predict a patient's Gleason score from an Illucix PET scan⁴
- Potential to apply the model to new indications

1. Telix media release 14 June 2022.

2. Telix ASX disclosure 27 April 2023.

3. Positron emission tomography.

4. L. Papp, et al, "Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga] Ga-PSMA-11 PET/MRI," *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 48, no. 6, pp. 1795-1805, 2021.

Reader Support: Enhancing molecular imaging

Developed by Telix in partnership with Invicro

Reader Support



Increases efficiency and reproducibility of imaging assessments:

- Automates lesion segmentation
- Automates identification of PSMA lesions including low SUV (<3) uptake
- Future potential to track individual lesions between scans to show changes over time

Pilot developed and being prepared for FDA and CE Mark filing:


- Model trained for use with Illuccix® as first commercial application
- Capability to expand utility for use with other near-term commercial-stage imaging agents (e.g. TLX250-CDx, TLX101-CDx)



Reader Support: Case study


AI may increase the efficiency and reproducibility of clinicians' imaging assessments

Case 1




Original scan AI removes normal uptake (blue) AI bone segmentation (red)

Case 2



Original scan AI removes normal uptake (blue) AI lymph node segmentation (pink)

Case 3




Original scan AI removes normal uptake (blue) AI prostate segmentation (green)

Clinical decision support designed for nuclear medicine

Dedicaid acquisition enhances predictive capabilities of Telix's AI platform

Two major components of the platform

- **Clinical Decision Support System (CDSS):** Rapidly generates indication-specific applications from available datasets
- **Automated Machine Learning (AutoML):** “Zero code” approach greatly reduces time, cost and level of expertise required to build, test and validate AI models from raw data
- Unique capability in the market and provides advanced AI modelling opportunities
- Proof of concept developed for prostate, breast and lung cancer¹
- First application - predicting Gleason score for primary prostate cancer, with potential to develop multiple applications across a variety of disease areas



Dedicaid provides a powerful AI development platform

Greatly enhances Telix's ability to rapidly generate new applications from imaging data



Favourably differentiated from competitor solutions

- Current AI solutions in nuclear medicine can support interpretation and reading of images – but lack prediction capability



Clinically focused

- Secure, transparent, and trusted; quality control reports accompanying each output provide a data integrity and evaluation confidence score



Strong alignment with Illuccix and Telix theranostic pipeline

- Driven by diagnostic imaging for predictive and prognostic capabilities, beyond just Illuccix®



Speed to market for new CDSS applications

- No computer coding expertise required to go from clinical hypothesis, to experimentation, validation and product

Telix AI™: Next steps

Go-to-market strategy



Regulatory filing

- Near-term availability to key opinion leaders as a research tool, establish validation data sets for key applications
- FDA 510(k) and CE Mark submission for platform and prostate cancer CDSS application (H2 2023)



Illuccix commercial alignment

- Build CDSS application supported by Illuccix
- Integrate Illuccix reader support for advanced modelling
- Align with existing reader training and image interpretation educational tools



Indication expansion

- Build CDSS applications and seek regulatory approval for other Telix pipeline assets (e.g. TLX250-CDx and TLX101-CDx)
- Develop predictive algorithms that link imaging to therapeutic outcomes by harnessing data from key ongoing studies (i.e. ProstACT SELECT)

Contact

Kyahn Williamson

SVP Investor Relations and Corporate
Communication

kyahn.williamson@telixpharma.com

